CT20126

colchicine-derived compound that promotes skin allograft survival by regulating the balance of Th1 and Th2 cytokine production; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cho, Young-Lai: 1 article (07/2008)
2.	Ha, Kwon-Soo: 1 article (07/2008)
3.	Hwang, Jong-Yun: 1 article (07/2008)
4.	Kim, Soon-Ok: 1 article (07/2008)
5.	Kim, Young-Myeong: 1 article (07/2008)
6.	Kwon, Young-Guen: 1 article (07/2008)
7.	Lee, Hansoo: 1 article (07/2008)
8.	Lee, Seon-Jin: 1 article (07/2008)
9.	Na, Hee-Jun: 1 article (07/2008)
10.	Nam, Woo-Dong: 1 article (07/2008)

Related Diseases

1.	Inflammation (Inflammations) 07/01/2008 - "These findings indicate that CT20126 exerts an anti-inflammatory effect through NF-kappaB-responsive inflammatory gene expression by inhibiting the NIK- and Akt-dependent canonical NF-kappaB pathway and can be used as a therapeutic agent for rheumatoid arthritis related to chronic inflammation."
2.	Rheumatoid Arthritis 07/01/2008 - "These findings indicate that CT20126 exerts an anti-inflammatory effect through NF-kappaB-responsive inflammatory gene expression by inhibiting the NIK- and Akt-dependent canonical NF-kappaB pathway and can be used as a therapeutic agent for rheumatoid arthritis related to chronic inflammation."
3.	Experimental Arthritis 07/01/2008 - "CT20126, a novel immunosuppressant, prevents collagen-induced arthritis through the down-regulation of inflammatory gene expression by inhibiting NF-kappaB activation."
4.	Arthritis (Polyarthritis) 07/01/2008 - "Furthermore, CT20126 significantly decreased the incidence and severity of arthritis as well as inhibited the expression of inflammatory cytokines, chemokines, iNOS, and cyclooxygenase-2 in the paws of collagen-induced arthritic mice. "

Related Drugs and Biologics

1.	Cyclooxygenase 2 (Cyclooxygenase-2)
2.	Chemokines
3.	NF-kappa B (NF-kB)
4.	Cytokines
5.	Immunosuppressive Agents (Immunosuppressants)
6.	Collagen